Agomab Spain S.L.U.

Address: Parque Empresarial De Touro Parcelas 26-27, Fonte Diaz

Sponsor Overview

assignment

Specializations

Gastrointestinal Fibrotic Disorders

Agomab Spain S.L.U. demonstrates a concentrated focus on addressing fibrotic complications within the gastrointestinal tract, particularly in patients with established inflammatory bowel conditions. The sponsor's research portfolio centers on therapeutic interventions targeting intestinal fibrosis and stricture formation, conditions that represent significant clinical challenges in chronic gastrointestinal disease management.

Crohn's Disease Strictures
Intestinal Fibrosis Mechanisms
Fibrostenotic Complications

The therapeutic development program emphasizes novel approaches to managing stricturing phenotypes in inflammatory bowel disease, exploring mechanisms that may prevent or reverse pathological tissue remodeling in the intestinal wall.

Inflammatory Bowel Disease Management

The sponsor maintains an active research presence in chronic inflammatory conditions of the digestive system, with particular attention to Crohn's disease and its structural complications. Research initiatives explore therapeutic strategies for patients experiencing progressive disease characterized by bowel wall thickening and luminal narrowing.

Chronic Intestinal Inflammation
Disease Progression Mechanisms
Structural Bowel Complications

Clinical investigations address the intersection of inflammation and tissue remodeling, focusing on patient populations with established fibrostenotic disease patterns that limit current therapeutic options.

Tissue Remodeling and Repair

Agomab Spain S.L.U. pursues research into biological processes governing extracellular matrix deposition and tissue architecture disruption within the gastrointestinal system. The therapeutic development strategy targets pathways involved in excessive collagen accumulation and aberrant wound healing responses that lead to functional impairment.

Pathological Fibrogenesis
Extracellular Matrix Regulation
Tissue Architecture Preservation

Research efforts concentrate on interventions that may modulate pro-fibrotic signaling cascades and restore normal tissue repair mechanisms in chronically inflamed intestinal segments.

Trial Name	Country	Status
A Phase 2a, Randomized, Placebo-controlled, Double-blind Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AGMB-129 in Patients with Fibrostenotic Crohn’s Disease	Austria Denmark Germany Italy Poland Spain	Not Recruiting
Evaluation of the Relative Bioavailability and Food Effect of AGMB-129 in Healthy Participants with Fibrostenotic Crohn’s Disease	Belgium	Not Recruiting
Investigation of AGMB-129 and Midazolam Interaction in Healthy Subjects for Fibrostenotic Crohn’s Disease Management	Belgium	Not Recruiting
Safety and Tolerability of AGMB-129 in Healthy Adults: A Dose-Escalation Study for Fibrostenotic Crohn’s Disease	Belgium	Not Recruiting